Articles tagged with Cancer Treatments
Researchers developed a simple, cost-effective blood test that detects Parkinson's disease long before symptoms emerge by analyzing transfer RNA fragments. The test has an accuracy surpassing existing clinical diagnostic tools and may alleviate uncertainty faced by patients and clinicians.
The study found that fecal microbiota transplantation (FMT) can outcompete H. pylori, producing antimicrobial peptides and metabolic byproducts to create a hostile environment. FMT may also mitigate adverse effects of antibiotic treatments, improving patient tolerance.
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
Researchers have developed a new approach to overcome treatment resistance in estrogen receptor-positive (ER+) breast cancer. Dual aromatase-steroid sulfatase inhibitors (DASIs) show promise in effectively blocking both enzymes involved in oestrogen production, potentially reducing tumour growth.
The study found that patients with coaxial silicone drains had lower analgesic consumption and better-preserved respiratory muscle strength during the first 2 postoperative days. This suggests that coaxial SIL drains can reduce postoperative pain and improve patient comfort and recovery following VATS lobectomy.
Living in disadvantaged neighborhoods is associated with a higher risk of mortality from breast cancer in Black women. Community-level interventions aimed at reducing environmental stressors and improving access to high-quality cancer care could help reduce racial disparities in breast cancer survival.
Isowalsuranolide activates autophagy-dependent cell death by targeting TrxR1/2, leading to ROS-mediated lysosomal biogenesis and reduced cell growth. The study reveals the TrxR1/2-p53-TFEB/TFE3 axis as a key regulator of cellular homeostasis in cancer.
Researchers develop innovative MSOT-AI technology to improve basal cell carcinoma diagnosis and surgical planning, reducing repeat procedures and improving patient outcomes. The technique captures detailed 3D views of tumours, enabling clearer insights into tumour boundaries.
A new case report presents a highly unusual combination of two benign ovarian tumors: serous cystadenofibroma and collision lesions. Accurate preoperative diagnosis is critical for effective treatment planning, and this case emphasizes the need for personalized evaluation of each ovarian mass.
Researchers have discovered a key cellular mechanism regulating mRNA vaccine delivery and stability, proposing a new paradigm for mRNA therapeutics. The study highlights the importance of N1-methylpseudouridine modification in enhancing mRNA vaccine effectiveness.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
The NCCN 2025 Annual Conference showcased the critical impact of cancer research on improving lives. The conference featured new research, discussions on AI in oncology care, and strategies for ensuring high-quality, person-centered cancer care.
Researchers at USC Viterbi have developed a new type of immune cell that can sense and destroy cancer cells for extended periods using focused ultrasound. This technology could overcome obstacles in treating tumors with immunotherapy while keeping healthy tissue safe.
Researchers at Osaka University identify a specific molecule, HLA-DRB1, that can be targeted by CAR-based therapy for AML. Engineered CAR T cells showed strong and specific anti-AML effects in vitro and in vivo with mice, without overt toxicity.
Researchers at Cornell University discovered that the FGR protein can induce cell differentiation in leukemia cells similar to retinoic acid treatment. The presence of FGR alone was enough to make these cells mature, producing well-known markers of maturation and expressing inhibitor of the cell cycle p27.
Researchers from Emory University are using the International Space Station to study cardiac cells and accelerate the development of cell-based regenerative therapies. The team's findings have led to multiple peer-reviewed publications and could significantly advance methods to produce cardiac cells for heart disease treatment.
Researchers created a highly detailed map of gastric cancer tissues using advanced mapping technologies, identifying distinct subgroups of cancer cells and evolutionary pathways that influence tumour behaviour. These insights could lead to more precise, targeted treatments that improve survival rates and reduce side effects.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
UC San Diego Health has earned The Joint Commission's Gold Seal of Approval for Advanced Certification in Spine Surgery, reflecting its dedication to patient safety and surgical innovation. The health system continues to provide consultation to other organizations exploring the certification.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A recent study has found that people diagnosed with colorectal cancer are more likely to die from cardiovascular causes, particularly in the first two years after diagnosis. The study analyzed data from over 630,000 US adults and found a 16% increased risk of cardiovascular mortality among those with colorectal cancer.
A comprehensive review of studies reveals that over 15% of caregivers of adult cancer patients suffer from post-traumatic stress disorder (PTSD). Caregivers with pre-existing mental health conditions and high caregiver burden are at greater risk. The study highlights the urgent need for proactive screening and support to prevent long-t...
The review article examines the relationship between anemia and retinopathy of prematurity, focusing on iron deficiency and underlying molecular mechanisms. Anemia reduces oxygen delivery to the retina, exacerbating hypoxia and promoting pathological neovascularization.
Researchers argue that the current paradigm of cancer as a genetic disease is unproductive due to inconsistencies in sequencing data. Alternative paradigms considering non-genetic processes, such as disruptions in gene regulatory networks and tissue organization, are proposed to guide future experiments.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
Researchers have discovered a protein called MdfA that enables bacteria to shut down into dormant spores under extreme conditions. This process allows bacteria to survive in uninhabitable places and evade hospital cleaning, making them potentially deadly superbugs.
Researchers have found a way to reactivate the body's natural ability to destroy excess cancer proteins by introducing synthetic RNA fragments that increase poison exon inclusion. This discovery could lead to game-changing therapies for aggressive cancers such as triple-negative breast cancer and certain brain tumors.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Recent research suggests that some invasive cancers diagnosed in early-stage breast cancer may not need immediate surgery, highlighting the importance of more precise screening methods for DCIS. The COMET trial found that at least half of invasive breast cancers take years to progress or may never progress at all.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Dr. Ronald Newbold has been appointed as the permanent CEO of Empire Discovery Institute (EDI), a non-profit drug discovery and development accelerator. With over 30 years of business development experience, Dr. Newbold will lead EDI's growth and expansion, including the addition of new programs and partnerships.
Researchers have identified ubiquitin-specific proteases as key regulators of programmed cell death pathways in breast cancer. The review explores the complex interactions between ubiquitination, cell death mechanisms, and cancer biology, laying the foundation for novel therapeutic strategies.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Professor Robert T. Schooley will present a talk at the 8th World Congress on Targeting Phage Therapy, exploring phage therapy advancements and necessary steps for widespread adoption. The congress will gather experts to discuss latest advances, challenges, and clinical applications of bacteriophage therapy.
Recent developments in fluorescent probes offer improved specificity and sensitivity for detecting hepatocellular carcinoma (HCC). Next-generation probes are being developed to enhance tissue penetration depth and probe specificity, potentially improving surgical outcomes.
Researchers develop a potential new treatment for rare genetic diseases characterized by low levels of specific proteins. By adding an artificial poly(A) tail to mRNA, they boost protein production and aim to improve symptoms in people with protein-deficient disorders.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A research team discovered that a genetically engineered bacterial strain, Designer Bacteria 1 (DB1), efficiently survives in tumor tissues while being cleared from normal tissues. This is due to the interactions between DB1 and tissue-resident memory CD8+ T cells, which are reinvigorated and expanded following therapy. The high expres...
Cervical cancer incidence increased in rural US counties, with higher rates among white women, likely due to lower screening coverage and diagnostic care utilization. Rural areas may experience heightened access barriers, contributing to lower HPV vaccine uptake.
Researchers have developed a specialized nanoscale material that illuminates cancer cells under freezing conditions, improving surgical precision. This technology enhances surgeons' ability to detect and remove cancer cells during cryosurgery.
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
A new genetic testing technique is being developed to help young cancer patients receive more targeted and less toxic treatments. The test analyzes DNA released into the bloodstream by cancer cells, offering a less invasive way to monitor tumor progression and identify new treatment targets.
This disorder has diverse etiologies, variable presentations, and different therapeutic responses. The proposed diagnostic algorithm can differentiate pediatric MF subtypes to improve patient outcomes.
Key molecular applications in diagnosing and managing hematopoietic and lymphocytic neoplasms include comprehensive mutational profiling, aiding accurate diagnosis and prognostication. The use of targeted therapies against specific genetic abnormalities further refines treatment selection.
Enodia Therapeutics, launched by Institut Pasteur and Argobio, leverages AI to develop selective inhibitors of the Sec61/translocon molecular complex for treating cancer, inflammatory diseases, and viral infections. The company's breakthrough technology has earned a prestigious Golden Ticket Award from Pfizer.
A pioneering study identified a crucial interaction between Helicobacter pylori and non-H. pylori bacteria in pre-cancerous stage of gastric cancer. Researchers found that bacterial leakage into deeper gastric tissues may represent a previously overlooked factor in cancer progression.
A global study found that social media influencers promote controversial medical tests with limited scientific evidence, often without mentioning potential harms. The tests include full-body MRI scans, genetic testing, blood tests, and gut microbiome tests. Experts warn that these tests can lead to overdiagnosis and overuse.
Researchers at MD Anderson Cancer Center have developed a novel antibody-toxin conjugate that stimulates the immune system to recognize and attack cancer cells. The new approach combines the benefits of ADCs with immunotherapies, allowing the body's natural immune response to limit side effects and prevent tumor recurrence.
The review delves into genetic, epigenetic, and molecular mechanisms driving tumor metastasis, highlighting the roles of chromosomal instability, epigenetic modifications, and tumor microenvironment interactions. It also discusses the impact of specific genetic mutations and RNA modifications on metastatic behavior.
Increased visceral adipose tissue density and decreased skeletal muscle area are predictors of post-esophagectomy pulmonary complications. Decreased skeletal muscle density is associated with poorer overall survival. Routine morphomic analysis can help identify patients at risk and tailor perioperative care.
Researchers found 276 differentially methylated markers specific to lung cancer in ctDNA, with a diagnostic prediction model successfully differentiating malignancy from benign disease. The study highlights the potential of DNA methylation as a biomarker for early diagnosis of non-small cell lung cancer.
Short-course corticosteroid treatment was associated with lower surgical site complications and in-hospital mortality in patients with postoperative acute lung injury following lung resection surgery. The optimal duration of corticosteroid treatment remains uncertain, highlighting the need to weigh benefits against adverse effects.
A new study has identified two cell types with distinct biological properties that respond differently to treatment after acquiring the same mutation. Understanding these differences is crucial for developing personalized therapies and preventing aggressive forms of cancer.
Researchers at Tel Aviv University have developed a novel method to measure PTEN gene activity, which is associated with cancer and autism. This breakthrough may lead to personalized therapeutics and earlier disease detection.
New research reveals aldosterone-producing adenomas harbor at least four distinct cell types, including cortisol-producing cells that contribute to unexpected health issues. The study also identifies potential role of lipid-associated macrophages in influencing hormone production and tumor growth.
Researchers introduce a dual threshold classifier to interpret circulating tumor DNA levels, enabling earlier detection of disease progression and personalized treatment. The study confirms that ctDNA levels are superior to traditional biomarkers like CA15-3.
Researchers developed a novel Ce6-GFFY molecule that forms stable macroparticles, allowing targeted tumor penetration. In vitro studies showed effective penetration and ROS production, while in vivo studies demonstrated prolonged half-life and effective drug uptake.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.